Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus
Open Access
- 22 June 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (8) , 893-899
Abstract
Rituximab (RTX), a chimeric monoclonal antibody (Ab) anti-CD20, is approved as a first-line treatment for moderate-to-severe pemphigus vulgaris. Its superiority compared with a conventional regimen of corticosteroids and mycophenolate mofetil has been demonstrated.1,2 The rate of relapse after RTX treatment increases over time. In the Ritux3 trial, around 25% of patients experienced relapse within the first 12 months, and some patients relapsed later on, suggesting the potential interest of maintenance infusions of RTX (NCT00784589). Multiple maintenance infusions have been associated with good clinical outcomes,3 although this systematic retreatment is not completely satisfactory because around 40% of patients do not experience relapse, even in the long term.1,2,4,5Keywords
This publication has 21 references indexed in Scilit:
- Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicitymAbs, 2015
- Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigusExperimental Dermatology, 2013
- Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell ResponseScience Translational Medicine, 2013
- Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigusJournal of Allergy and Clinical Immunology, 2012
- Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Immunogenicity of rituximab in patients with severe pemphigusClinical Immunology, 2009
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnnals of the Rheumatic Diseases, 2008
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaBlood, 2003